Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8273381 | 0.94 | GHSR (0.88) | GHSR | |
| SCHEMBL8272398 | 0.92 | GHSR (0.84) | GHSR | |
| SCHEMBL8272399 | 0.91 | GHSR (0.83) | GHSR | |
| SCHEMBL2730085 | 0.90 | GHSR (0.84) | GHSR | |
| SCHEMBL13612886 | 0.90 | GHSR (0.81) | GHSR | |
| SCHEMBL14047028 | 0.89 | GHSR (0.80) | GHSR | |
| SCHEMBL13626843 | 0.88 | GHSR (0.79) | GHSR | |
| SCHEMBL13063919 | 0.88 | GHSR (0.88) | GHSR | |
| SCHEMBL14092308 | 0.88 | GHSR (0.88) | GHSR | |
| SCHEMBL9882982 | 0.88 | GHSR (0.88) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275648-A1 | MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME | OCERA THERAPEUTICS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275648-A1 | MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME | OCERA THERAPEUTICS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7550431-B2 | Spatially-defined macrocycles incorporating peptide bond surrogates | TRANZYME PHARMA INC. (CA) | 2009-06-23 | — | — | US | disclosed |
| US-7550431-B2 | Spatially-defined macrocycles incorporating peptide bond surrogates | TRANZYME PHARMA INC. (CA) | 2009-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275648-A1 | MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME | GHSR, GIPR, GHRHR | GHSR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.